CDK7 and neoplasm: In NSCLC cells, the CDK7 inhibitor THZ1 inhibits MYC transcriptional activity by downregulating p38α, thereby suppressing PD-L1 expression and improving the anti-tumor immunity against PD-1 therapy in vivo by recruiting infiltrating CD8+ T cells [210].